Bigger rivals slow BNP (B-type natriuretic peptide) test maker Biosite's growth spurt
This article was originally published in Clinica
Biosite, which in 2000 was the first company to launch in the US a blood test for B-type natriuretic peptide (BNP) to diagnose and assess congestive heart failure (CHF), is beginning to feel the squeeze from the competition.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.